Sanuwave Health (NASDAQ:SNWV – Get Free Report) posted its quarterly earnings results on Tuesday. The company reported ($0.16) EPS for the quarter, missing the consensus estimate of $0.01 by ($0.17), FiscalAI reports. Sanuwave Health had a net margin of 32.38% and a return on equity of 1,728.10%. The firm had revenue of $8.58 million during the quarter, compared to analyst estimates of $13.75 million.
Sanuwave Health Stock Up 1.6%
Shares of SNWV opened at $1.88 on Wednesday. The company has a market capitalization of $16.17 million, a P/E ratio of 7.71 and a beta of 1.47. The company has a debt-to-equity ratio of 4.87, a current ratio of 1.28 and a quick ratio of 0.89. Sanuwave Health has a one year low of $1.75 and a one year high of $36.20. The business’s 50 day simple moving average is $4.68 and its 200-day simple moving average is $12.78.
Analyst Ratings Changes
Separately, Weiss Ratings upgraded shares of Sanuwave Health from a “sell (d)” rating to a “sell (d+)” rating in a research report on Wednesday, November 4th. One equities research analyst has rated the stock with a Buy rating and two have assigned a Sell rating to the stock. According to MarketBeat, Sanuwave Health presently has a consensus rating of “Reduce” and an average price target of $47.00.
Get Our Latest Stock Report on SNWV
About Sanuwave Health
SANUWAVE Health, Inc. is a medical technology company focused on regenerative medicine and advanced wound-care solutions. The company develops and commercializes noninvasive devices that use extracorporeal shock wave technology to stimulate biological responses in damaged or difficult-to-heal tissue. Its principal product is the dermaPACE system, which is designed to deliver acoustic shock waves to wound areas, including chronic diabetic foot ulcers. SANUWAVE has also pursued additional applications for its platform in areas such as orthopedic and soft-tissue healing, although the availability and regulatory status of specific products may vary by geography.
Featured Stories
- Five stocks we like better than Sanuwave Health
- Anthropic’s Trillion-Dollar IPO Could Give Cloud Giants a Double Win
- The AI Debt Bill Is Coming Due, But Biotech Has Revenue to Show for the Boom
- 3 Insider Selling Stories; 3 Different Signals for Investors
- The Trade Desk Beats on Revenue, But the Fine Print Matters
Receive News & Ratings for Sanuwave Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sanuwave Health and related companies with MarketBeat.com's FREE daily email newsletter.
